SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Ruddy Dalfeor(Centro de Pesquisas Oncológicas), JR Brown(Dana-Farber Cancer Institute), Jamie Hirata(Universidad San Carlos), S. Opat(Monash Health), Paolo Ghia(Vita-Salute San Raffaele University), Patricia Walker(Peninsula Health), Tian Tian(Harbin Medical University), Constantine S. Tam(The Alfred Hospital), T Munir(Leeds Teaching Hospitals NHS Trust), Mazyar Shadman(University of Washington)
Cited by 0
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890